Logo image of NTRB

NUTRIBAND INC (NTRB) Stock Fundamental Analysis

NASDAQ:NTRB - Nasdaq - US67092M2089 - Common Stock - Currency: USD

5.72  +0.04 (+0.7%)

Fundamental Rating

3

Taking everything into account, NTRB scores 3 out of 10 in our fundamental rating. NTRB was compared to 198 industry peers in the Pharmaceuticals industry. While NTRB seems to be doing ok healthwise, there are quite some concerns on its profitability. NTRB is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NTRB has reported negative net income.
NTRB had a negative operating cash flow in the past year.
In the past 5 years NTRB always reported negative net income.
In the past 5 years NTRB always reported negative operating cash flow.
NTRB Yearly Net Income VS EBIT VS OCF VS FCFNTRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

NTRB has a worse Return On Assets (-54.59%) than 61.62% of its industry peers.
Looking at the Return On Equity, with a value of -60.96%, NTRB is in line with its industry, outperforming 52.53% of the companies in the same industry.
Industry RankSector Rank
ROA -54.59%
ROE -60.96%
ROIC N/A
ROA(3y)-56.8%
ROA(5y)-64.75%
ROE(3y)-63.74%
ROE(5y)-357.53%
ROIC(3y)N/A
ROIC(5y)N/A
NTRB Yearly ROA, ROE, ROICNTRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

NTRB has a Gross Margin (31.59%) which is in line with its industry peers.
In the last couple of years the Gross Margin of NTRB has grown nicely.
NTRB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.59%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.59%
GM growth 5YN/A
NTRB Yearly Profit, Operating, Gross MarginsNTRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

NTRB does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTRB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for NTRB has been increased compared to 5 years ago.
NTRB has a worse debt/assets ratio than last year.
NTRB Yearly Shares OutstandingNTRB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
NTRB Yearly Total Debt VS Total AssetsNTRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

An Altman-Z score of 24.34 indicates that NTRB is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 24.34, NTRB belongs to the top of the industry, outperforming 94.44% of the companies in the same industry.
NTRB has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of NTRB (0.01) is better than 60.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 24.34
ROIC/WACCN/A
WACC9.79%
NTRB Yearly LT Debt VS Equity VS FCFNTRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

NTRB has a Current Ratio of 4.96. This indicates that NTRB is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.96, NTRB is doing good in the industry, outperforming 72.73% of the companies in the same industry.
A Quick Ratio of 4.83 indicates that NTRB has no problem at all paying its short term obligations.
NTRB's Quick ratio of 4.83 is fine compared to the rest of the industry. NTRB outperforms 73.23% of its industry peers.
Industry RankSector Rank
Current Ratio 4.96
Quick Ratio 4.83
NTRB Yearly Current Assets VS Current LiabilitesNTRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

More info and screens

8

3. Growth

3.1 Past

NTRB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.09%, which is quite impressive.
Looking at the last year, NTRB shows a very strong growth in Revenue. The Revenue has grown by 46.22%.
NTRB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 77.69% yearly.
EPS 1Y (TTM)32.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)46.22%
Revenue growth 3Y77.69%
Revenue growth 5YN/A
Sales Q2Q%22%

3.2 Future

Based on estimates for the next years, NTRB will show a very strong growth in Earnings Per Share. The EPS will grow by 54.57% on average per year.
Based on estimates for the next years, NTRB will show a very strong growth in Revenue. The Revenue will grow by 140.82% on average per year.
EPS Next Y57.12%
EPS Next 2Y-5.76%
EPS Next 3Y-1.44%
EPS Next 5Y54.57%
Revenue Next Year45.91%
Revenue Next 2Y-0.46%
Revenue Next 3Y84.92%
Revenue Next 5Y140.82%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NTRB Yearly Revenue VS EstimatesNTRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
NTRB Yearly EPS VS EstimatesNTRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NTRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NTRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTRB Price Earnings VS Forward Price EarningsNTRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTRB Per share dataNTRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.76%
EPS Next 3Y-1.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NTRB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUTRIBAND INC

NASDAQ:NTRB (5/9/2025, 8:12:14 PM)

5.72

+0.04 (+0.7%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-28 2025-04-28/amc
Earnings (Next)05-29 2025-05-29
Inst Owners2.21%
Inst Owner Change0.08%
Ins Owners54.01%
Ins Owner Change0%
Market Cap63.78M
Analysts82.86
Price Target13.26 (131.82%)
Short Float %5.53%
Short Ratio6.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.55
P/FCF N/A
P/OCF N/A
P/B 5.68
P/tB 11.33
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0.18
BVpS1.01
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.59%
ROE -60.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.59%
FCFM N/A
ROA(3y)-56.8%
ROA(5y)-64.75%
ROE(3y)-63.74%
ROE(5y)-357.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.59%
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 50.16%
Cap/Sales 6.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.96
Quick Ratio 4.83
Altman-Z 24.34
F-Score4
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)22.82%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.01%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y57.12%
EPS Next 2Y-5.76%
EPS Next 3Y-1.44%
EPS Next 5Y54.57%
Revenue 1Y (TTM)46.22%
Revenue growth 3Y77.69%
Revenue growth 5YN/A
Sales Q2Q%22%
Revenue Next Year45.91%
Revenue Next 2Y-0.46%
Revenue Next 3Y84.92%
Revenue Next 5Y140.82%
EBIT growth 1Y-22.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.09%
OCF growth 3YN/A
OCF growth 5YN/A